Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Interferon regulatory factor 5 (IRF5) belongs to a family of transcription factors, originally implicated in antiviral responses and interferon production. However, studies conducted in different laboratories over the last decade have placed IRF5 as a central regulator of the inflammatory response. It has become clear that IRF5 contributes to the pathogenesis of many inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus. Given the role of IRF5 in physiology and disease, IRF5 represents a potential therapeutic target. However, despite a significant interest from the pharmaceutical industry, inhibitors that interfere with the IRF5 pathway remain elusive. Here, we review the advances made by various studies in targeting multiple steps of signalling leading to IRF5 activation with their therapeutic potential, and the possible complications of such strategies are discussed.

Original publication

DOI

10.1111/febs.14654

Type

Journal article

Journal

FEBS J

Publication Date

05/2019

Volume

286

Pages

1624 - 1637

Keywords

autoimmune diseases, inflammation, interferon regulatory factor 5, therapy, transcription factor, Autoimmune Diseases, DNA, Dimerization, Gene Expression Regulation, Genetic Therapy, Humans, Inflammation, Interferon Regulatory Factors, Molecular Targeted Therapy, Phosphorylation, Protein Binding, Protein Interaction Mapping, Protein Kinase Inhibitors, Protein Processing, Post-Translational, RNA Interference, RNA, Small Interfering, Signal Transduction, Toll-Like Receptors, Transcription, Genetic